Search results for "Cholesterolemia"

showing 10 items of 252 documents

Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and no…

2020

Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age.The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients.The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years.Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, tha…

Malemedicine.medical_specialty[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismFamilial hypercholesterolemia030204 cardiovascular system & hematologyCohort StudiesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineSurveys and QuestionnairesInternal MedicinemedicineHumansIn patient030212 general & internal medicineMyocardial infarctionRegistriesNon-ST Elevated Myocardial InfarctionStrokeComputingMilieux_MISCELLANEOUSAgedNutrition and Dieteticsbusiness.industryST elevationHazard ratioMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthCohortST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFemaleFranceHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessJournal of clinical lipidology
researchProduct

New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!

2015

Malemedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismHypercholesterolemiamedicine.diseaseEndocrinologyEndocrinologyNew onset diabetesInternal medicineDiabetes MellitusmedicineHumansFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsMetabolic syndromebusinessMetabolism
researchProduct

Portulaca oleracea reduces triglyceridemia, cholesterolemia, and improves lecithin: cholesterol acyltransferase activity in rats fed enriched-cholest…

2014

Abstract Purpose The effects of Portulaca oleracea ( Po ) lyophilized aqueous extract were determined on the serum high-density lipoproteins (HDL 2 and HDL 3 ) amounts and composition, as well as on lecithin: cholesterol acyltansferase (LCAT) activity. Methods Male Wistar rats ( n  = 12) were fed on 1% cholesterol-enriched diet for 10 days. After this phase, hypercholesterolemic rats (HC) were divided into two groups fed the same diet supplemented or not with Portulaca oleracea ( Po -HC) (0.5%) for four weeks. Results Serum total cholesterol (TC) and triacylglycerols (TG), and liver TG values were respectively 1.6-, 1.8-, and 1.6-fold lower in Po -HC than in HC group. Cholesterol concentrat…

Malemedicine.medical_specialtyfood.ingredientHypercholesterolemiaPharmaceutical SciencePortulacaPortulacaLecithinCholesterol DietaryPhosphatidylcholine-Sterol O-Acyltransferasechemistry.chemical_compoundfoodInternal medicineDrug DiscoverymedicineAnimalsRats WistarTriglyceridesHypolipidemic AgentsPharmacologychemistry.chemical_classificationHypertriglyceridemiaChromatographybiologyCholesterolPlant ExtractsReverse cholesterol transportbiology.organism_classificationPlant LeavesEnzymeEndocrinologyCholesterolComplementary and alternative medicinechemistryLiverLecithin—cholesterol acyltransferasebiology.proteinMolecular Medicinelipids (amino acids peptides and proteins)Composition (visual arts)Acyl groupPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.

2018

INTRODUCTION Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid-lowering therapy (LLT) before the final step of commencing chronic lipoprotein apheresis (LA). Data are scarce on patients who, after escalation of LLT with PCSK9 antibodies, have commenced chronic LA or PCSK9 antibody treatment during ongoing long-term LA. PATIENTS AND METHODS In this study, a cohort of 110 patients with established atherosclerotic cardiovascular disease (ASCVD) due to hypercholesterolemia or concomitant lipoprotein(a)-hyperlipoproteinemia, who received PCSK9 antibodies for the first time during routine care, were consecutivel…

Malemedicine.medical_specialtymedicine.drug_classLipoproteinsHypercholesterolemia030204 cardiovascular system & hematologyMonoclonal antibodyGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEnzyme InhibitorsAdverse effectbiologybusiness.industryPCSK9PCSK9 InhibitorsAntibodies MonoclonalHematologyGeneral MedicineLipoprotein(a)Cholesterol LDLMiddle AgedAtherosclerosisCombined Modality TherapyLipidsDiscontinuationConcomitantCohortbiology.proteinBlood Component RemovalFemaleAntibodyProprotein Convertase 9business030215 immunologyLipoprotein(a)Journal of clinical apheresis
researchProduct

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patien…

2015

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg Q2W (also 1-mL volume) in patients not achieving their LDL-C target. Primary endpoi…

Monoclonal antibodymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaInjections SubcutaneousHypercholesterolemiaUrology030204 cardiovascular system & hematologyPharmacologyAntibodies Monoclonal Humanizedlaw.inventionPCSK9Rosuvastatin03 medical and health sciences0302 clinical medicineDouble-Blind MethodEzetimibeRandomized controlled triallawmedicineClinical endpointHumansLow-density lipoprotein cholesterolRosuvastatinIn patient030212 general & internal medicineRosuvastatin CalciumAlirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin; Cardiology and Cardiovascular MedicineRetrospective StudiesAlirocumabDose-Response Relationship Drugbusiness.industryAnticholesteremic AgentsPCSK9Antibodies Monoclonalnutritional and metabolic diseasesCholesterol LDLEzetimibeRosuvastatin CalciumTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineFollow-Up StudiesAlirocumabmedicine.drugAtherosclerosis
researchProduct

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.

2006

The aim of our study was to explore some potential pleiotropic effects of atorvastatin, after stenting in the iliac arteries of normocholesterolemic rabbits. On day 0, 27 rabbits underwent stent implantation and were randomized into either the control group (standard chow, CTRL, n = 15) or the atorvastatin group (10 mg/kg/d per os, Ator, n = 12). On day 30, the stented arteries were harvested for histomorphometry and neointimal analysis [macrophages, matrix metalloproteinases (MMP-2), tissue inhibitor of metalloproteinase-2, vascular smooth muscle cells, and collagen]. Atorvastatin did not induce significant histomorphometric and inflammatory modifications but reduced neointimal expression …

NeointimaMalemedicine.medical_specialtyStatinVascular smooth musclemedicine.drug_classAtorvastatinHypercholesterolemiaUrologyMatrix metalloproteinaseIliac ArteryMuscle Smooth VascularRestenosisInternal medicinemedicineAtorvastatinAnimalsPyrrolesPharmacologyTissue Inhibitor of Metalloproteinase-2Cellular densityChemistrymedicine.diseaseImmunohistochemistryHeptanoic AcidsCardiologyMatrix Metalloproteinase 2StentsStatin therapyRabbitsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineTunica Intimamedicine.drugJournal of cardiovascular pharmacology
researchProduct

The PCSK9 gene: a new gene controlling cholesterolemia

2007

The distribution of cholesterol plasma is regulated by complex interactions between genes and environmental factors. Mutations of PCSK9 gene seem to modulate the levels of LDLC. Mutations of PCSK9 gene with gain of function are associated to hypercholesterolemia and mutations with loss of function determine hypocholesterolemia.

PCSK9Settore MED/09 - Medicina Internahypercholesterolemiamutation
researchProduct

A simplified method to quantitate atherosclerosis in the rabbit aorta.

2001

A simple method to quantitatively evaluate atherosclerosis in the rabbit aorta by measuring macroscopic lesion areas (%) was attempted in the present study. Ten female New Zealand white rabbits were fed on a cholesterol-rich diet (5/1000 g of food) during 4 months. Five of them were oophorectomized at the beginning and all were sacrificed at the end. Total levels of cholesterol increased from 50.7+/-14.7 mg/dl to 782.8+/-296.0. No significant differences were observed between oophorectomized and intact rabbits. At 4 months, the cholesterol-rich diet caused in both, intact and oophorectomized rabbits, atherosclerotic lesions affecting 17 and 46% of the aortic surface, respectively. This meth…

Pathologymedicine.medical_specialtyOvariectomyHypercholesterolemiaCoronary Artery DiseaseSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyLesionchemistry.chemical_compoundPredictive Value of Testsmedicine.arterymedicineImage Processing Computer-AssistedAnimalsNew zealand whiteAortaAortic atherosclerosisAortaLagomorphabiologyCholesterolVascular diseasebusiness.industryRabbit aortaObstetrics and GynecologyAnatomybiology.organism_classificationmedicine.diseaseDisease Models AnimalchemistryFemaleRabbitsmedicine.symptombusinessMaturitas
researchProduct

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

2019

Purpose of Review Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With “central support,” more centers and countries participated in the project. Subsequently, individ…

Pediatricsmedicine.medical_specialtyInternational CooperationFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyTreatment resultsAntibodies Monoclonal HumanizedFHHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineTotal cholesterolmedicineHumansMass ScreeningEffective treatment030212 general & internal medicineScreenPro FHLDL-CAlirocumabInternational networkEvidence-Based Medicine Clinical Trials and Their Interpretations (L. Roever Section Editor)business.industryAnticholesteremic AgentsIncidencePCSK9 InhibitorsScreen and treatmedicine.diseaseEvolocumab3. Good healthEuropeEvolocumabProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessDelivery of Health CareAlirocumabCurrent Atherosclerosis Reports
researchProduct